SAN FRANCISCO, Feb. 24, 2016 /PRNewswire/ -- entrotech life sciences (ELS) (www.entrotechlifesciences.com) recently announced the availability of FDA-Cleared ChloraDerm™ in a new 1.75"x 1.75" configuration, ideal for pediatric patient use. ChloraDerm™ is the first and only transparent film dressing containing the Chlorhexidine Advantage™, a safe, colophony-and acid-free, edge-to-edge chlorhexidine matrix with effectiveness against multi-drug-resistant organisms, including MRSA for at least seven days.
The ChloraDerm platform was recently launched by entrotech life sciences, an innovative company that is taking its expertise in life-saving products from the military battlefield to the hospital bed-side. To support the commercialization of the new line for the healthcare market, ELS hired market experts Jack Querio and Aime' Lenz to its Executive Team beginning in 2015.
"We have always felt that the pediatric setting deserves the best technologies available and should be integral to our commercial strategy," said ELS CEO Jim McGuire, "Both Jack and Aime have the deep expertise and knowledge to advance our mission to save lives and will play instrumental roles in finding new ways to deliver Infection Prevention solutions to healthcare providers around the globe."
Querio, National and Government Account Authority, has spent more than 32 years in the biotech, medical device, pharmaceutical and consumer products industries with companies such as Johnson & Johnson, Zimmer Holdings and Medline Industries. During his tenure at Johnson & Johnson, Jack led national account (GPO/IDN) and government (VA/DoD) teams with multi-billion dollar annual revenue responsibility. Jack has worked in Washington, DC with lobbyists, patient advocacy groups, congressional leaders and staff, and legal entities on various programs to advance public health and safety.
Jack Querio commented, "In my 30+ years in this industry I have never seen a product, for its indication, better than ChloraDerm™. Our antimicrobial technology platform sets in motion a future of innovation that can positively impact all patients, including children, for many years to come."
Lenz, Antimicrobial Commercialization Expert, has committed her career to minimizing the global problem of Healthcare-Acquired Infections (HAIs) through the commercial advancement of novel medical technologies and recently published "The Evolving Business of Healthcare: Key Issues in Healthcare Reform for Infection Prevention Professionals." She was a leader in the transformational commercial effort to shift clinical practice in the United States towards the use of chlorhexidine for patient preoperative skin preparation in pediatric and adult settings, which has significantly reduced infections related to catheters and surgical sites.
"To experience how quickly entrotech life sciences develops and manufactures innovations with huge technical and regulatory hurdles is a rarity in this industry," said Aime' Lenz "I joined ELS because of their talented team, leadership in solving problems, and their ingenuity and speed in delivering FDA-cleared chlorhexidine solutions to improve public health of pediatric and adult patients by preventing infections."
ELS is also supported by a prestigious Board of Directors including Former U.S. Surgeon General, Dr. Kenneth Moritsugu, and veteran Silicon Valley investor and consultant, Dr. Morton Grosser.
ChloraDerm™ is used to cover and secure primary dressings and protect wounds with percutaneous medical devices that could result in a central line associated bloodstream infection (CLABSI). ChloraDerm achieves >4 Log10 reduction against yeasts and gram positive and negative bacteria, including multiple drug-resistant organisms (MRSA, MRSE, VRE, MDR. Compared to common non-antimicrobial dressings, ChloraDerm™ demonstrates substantially greater effectiveness against these organisms at one, three and seven days, without adding increased cost or complexity. CLABSI's afflict nearly 100,000 people per year and can cause severe harm or death. The 2011 CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections recommend Chlorhexidine impregnated dressings be considered for Central Venous Catheter CLABSI prevention.1
about entrotech life sciences
entrotech life sciences (ELS | San Francisco, CA) pioneered a platform technology that eluded researchers for the past 20 years through the invention of a patent-pending, non-thermal process for creating polymeric materials containing active chlorhexidine, the most effective antimicrobial for reducing skin bacteria. entrotech life sciences helps healthcare professionals committed to infection prevention rethink what is possible in protection of catheter and surgical patients. ELS is affiliated with Entrogroup (est. 1999), an organization focused on inventing advanced lifesaving combat military products, smart device protectors, and environmentally-friendly, and lightweight paint appliques. Visit: www.entrotechlifesciences.com/chloraderm
SOURCE entrotech life sciences